MX2022003873A - Inhibidores de 1,6-naftiridina sustituida de cdk5. - Google Patents

Inhibidores de 1,6-naftiridina sustituida de cdk5.

Info

Publication number
MX2022003873A
MX2022003873A MX2022003873A MX2022003873A MX2022003873A MX 2022003873 A MX2022003873 A MX 2022003873A MX 2022003873 A MX2022003873 A MX 2022003873A MX 2022003873 A MX2022003873 A MX 2022003873A MX 2022003873 A MX2022003873 A MX 2022003873A
Authority
MX
Mexico
Prior art keywords
cdk5
naphthyridine
inhibitors
substituted
kidney
Prior art date
Application number
MX2022003873A
Other languages
English (en)
Inventor
Mark W Ledeboer
Matthew H Daniels
Maolin Yu
Goran Malojcic
Brett D Williams
Jean-Christophe P Harmange
Jenna Lijie Wang
Original Assignee
Goldfinch Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Goldfinch Bio Inc filed Critical Goldfinch Bio Inc
Publication of MX2022003873A publication Critical patent/MX2022003873A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se divulgan compuestos con la fórmula estructural I y sales y composiciones farmacéuticas relacionadas. También se divulgan métodos terapéuticos, p. ej., para tratar enfermedades y afecciones como enfermedad renal, insuficiencia renal, cálculos renales o enfermedad poliquística de riñón, al utilizar los compuestos de fórmula (I) y sales y composiciones farmacéuticas relacionadas.
MX2022003873A 2019-10-01 2020-10-01 Inhibidores de 1,6-naftiridina sustituida de cdk5. MX2022003873A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962908952P 2019-10-01 2019-10-01
US202063050384P 2020-07-10 2020-07-10
PCT/US2020/053756 WO2021067569A1 (en) 2019-10-01 2020-10-01 Substituted 1, 6-naphthyridine inhibitors of cdk5

Publications (1)

Publication Number Publication Date
MX2022003873A true MX2022003873A (es) 2022-06-02

Family

ID=75337553

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022003873A MX2022003873A (es) 2019-10-01 2020-10-01 Inhibidores de 1,6-naftiridina sustituida de cdk5.

Country Status (11)

Country Link
US (1) US20220389009A1 (es)
EP (1) EP4037683A1 (es)
JP (1) JP2022550539A (es)
KR (1) KR20220099958A (es)
CN (1) CN114761000A (es)
AU (1) AU2020357865A1 (es)
BR (1) BR112022005706A2 (es)
CA (1) CA3156268A1 (es)
IL (1) IL291785A (es)
MX (1) MX2022003873A (es)
WO (1) WO2021067569A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR122928A1 (es) * 2020-07-10 2022-10-19 Goldfinch Bio Inc 1,6-naftiridinas sustituidas inhibidoras de cdk5
JP2024513227A (ja) 2021-04-05 2024-03-22 ハリア・セラピューティクス・インコーポレイテッド Ｎｅｋ７阻害剤

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2146782T3 (es) * 1994-11-14 2000-08-16 Warner Lambert Co 6-aril-pirido(2,3-d)pirimidinas y naftiridinas para la inhibicion de la proliferacion celular inducida por la proteina tirosina quinasa.
ES2235353T3 (es) * 1997-08-20 2005-07-01 Warner-Lambert Company Llc Naftridonas para inhibir la proteina tirasina quinasa y proliferacion celular mediada por la quinasa del ciclo celular.
US7507748B2 (en) * 2004-07-22 2009-03-24 Amgen Inc. Substituted aryl-amine derivatives and methods of use
CA2684147A1 (en) * 2007-05-15 2008-11-27 Boehringer Ingelheim International Gmbh Urotensin ii receptor antagonists
GB201216018D0 (en) * 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Pharmacologically active compounds

Also Published As

Publication number Publication date
IL291785A (en) 2022-06-01
EP4037683A1 (en) 2022-08-10
WO2021067569A8 (en) 2022-04-21
KR20220099958A (ko) 2022-07-14
CA3156268A1 (en) 2021-04-08
BR112022005706A2 (pt) 2022-06-21
US20220389009A1 (en) 2022-12-08
CN114761000A (zh) 2022-07-15
JP2022550539A (ja) 2022-12-02
WO2021067569A1 (en) 2021-04-08
AU2020357865A1 (en) 2022-04-28

Similar Documents

Publication Publication Date Title
EA202092896A1 (ru) Гетероциклические и гетероарильные соединения для лечения болезни гентингтона
WO2020097537A3 (en) Fused ring compounds
PH12021500014A1 (en) Fused ring compounds
WO2017205536A3 (en) Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer
EA201991399A1 (ru) Аминотриазолопиридиновые соединения и их применение в лечении рака
EA202092899A1 (ru) Гетероарильные соединения для лечения болезни гентингтона
WO2019055966A3 (en) PYRIDAZINONES AND METHODS OF USE
PH12020550881A1 (en) Substituted bicyclic heterocyclic compounds as prmt5 inhibitors
EA201792619A1 (ru) Нафтиридиновые соединения в качестве ингибиторов jak киназы
PH12018500958A1 (en) Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer
EA201691428A1 (ru) Бициклические гетероциклические производные в качестве ингибиторов irak4
EA201692095A1 (ru) Имидазо[4,5-c]хинолин-2-оновые соединения и их применение в лечении рака
EA201890650A1 (ru) ПРОИЗВОДНЫЕ 8-[6-[3-(АМИНО)ПРОПОКСИ]-3-ПИРИДИЛ]-1-ИЗОПРОПИЛ-ИМИДАЗО[4,5-c]ХИНОЛИН-2-ОНА В КАЧЕСТВЕ СЕЛЕКТИВНЫХ МОДУЛЯТОРОВ КИНАЗЫ МУТАЦИИ АТАКСИИ-ТЕЛЕАНГИЭКТАЗИИ (ATM) ДЛЯ ЛЕЧЕНИЯ РАКА
EA202090413A1 (ru) Пиразоло- и триазолобициклические соединения в качестве ингибиторов jak киназы
NO20090723L (no) Kondenserte heterosykliske derivater og fremgangsmater for anvendelse
MX2021015935A (es) Formas de sal de acido bempedoico y metodos para utilizar el mismo.
EA201892436A1 (ru) Пиримидиновые соединения в качестве ингибиторов jak киназы
PH12021550443A1 (en) Pyridazinones and methods of use thereof
EA201990678A1 (ru) Гетероарилкарбоксамидные соединения в качестве ингибиторов ripk2
EP4342473A3 (en) Compounds useful in hiv therapy
MX2022003873A (es) Inhibidores de 1,6-naftiridina sustituida de cdk5.
AU2020231934A8 (en) Compounds useful in HIV therapy
MX2021002878A (es) Inhibidores de cd73 y usos farmaceuticos de los mismos.
MX2022008627A (es) Pirazolo-pirimidinas sustituidas y usos de las mismas.
PH12021550143A1 (en) Pyridopyrimidines as histamine h4-receptor inhibitors